Skip to main content

Advertisement

SpringerLink
Log in

Neuropathy-Inducing Effects of Eribulin Mesylate Versus Paclitaxel in Mice with Preexisting Neuropathy

  • Original Article
  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Eribulin mesylate (E7389, INN:eribulin mesilate Halaven®) is a non-taxane microtubule dynamics inhibitor currently in clinical use for advanced breast cancer. Other microtubule-targeting agents for breast cancer, including paclitaxel and ixabepilone, display a common treatment dose-limiting toxicity of peripheral neuropathy (PN). In an earlier study, we found eribulin mesylate had a lower propensity to induce PN in mice than either paclitaxel or ixabepilone. In the current study, we compared additional PN induced by paclitaxel versus eribulin mesylate when administered to mice with preexisting paclitaxel-induced PN. Initially, paclitaxel at 0.75 × its maximum tolerated dose (MTD; 22.5 mg/kg) was given on a Q2Dx3 regimen for 2 weeks. The second chemotherapy was 0.5 MTD eribulin mesylate (0.875 mg/kg) or paclitaxel (15 mg/kg) on a similar regimen, starting 2 weeks after the first. Initial paclitaxel treatment produced significant decreases in caudal nerve conduction velocity (NCV; averaging 19.5 ± 1 and 22.2 ± 1.3 %, p < 0.001) and amplitude (averaging 53.2 ± 2.6 and 72.4 ± 2.1 %, p < 0.001) versus vehicle when measured 24 h or 2 weeks after dosing cessation, respectively. Additional 0.5 MTD paclitaxel further reduced caudal NCV and amplitude relative to immediately before initiation of the second regimen (by 11 ± 2.1 and 59.2 ± 5 %, p < 0.01, respectively). In contrast, 0.5 MTD eribulin mesylate caused no further decrease in caudal NCV. In conclusion, unlike additional paclitaxel treatment, eribulin mesylate administered to mice with preexisting paclitaxel-induced PN had limited additional deleterious effects at 6 weeks. These preclinical data suggest that eribulin mesylate may have reduced tendency to exacerbate preexisting paclitaxel-induced PN in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Apfel SC, Lipton RB, Arezzo JC, Kessler JA (1991) Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29:87–90

    Article  PubMed  CAS  Google Scholar 

  • Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2000) Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res 887:239–249

    Article  PubMed  CAS  Google Scholar 

  • Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A (2009) Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 6:620–629

    Article  PubMed  CAS  Google Scholar 

  • Boyle FM, Wheeler HR, Shenfield GM (1999) Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41:107–116

    Article  PubMed  CAS  Google Scholar 

  • Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G (1995a) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75:1141–1150

    Article  PubMed  CAS  Google Scholar 

  • Cavaletti G, Tredici G, Braga M, Tazzari S (1995b) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133:64–72

    Article  PubMed  CAS  Google Scholar 

  • Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G (1997) Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137–145

    PubMed  CAS  Google Scholar 

  • Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS (1998) Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43:46–55

    Article  PubMed  CAS  Google Scholar 

  • Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70:1866–1875

    Article  PubMed  CAS  Google Scholar 

  • Dina OA, Chen X, Reichling D, Levine JD (2001) Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 108:507–515

    Article  PubMed  CAS  Google Scholar 

  • Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J (1997) Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965–1973

    PubMed  CAS  Google Scholar 

  • Griffin JW, George R, Ho T (1993) Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 52:553–560

    Article  PubMed  CAS  Google Scholar 

  • Guastalla JP 3rd, Dieras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89(Suppl 3):S16–S22

    Article  PubMed  CAS  Google Scholar 

  • Hagiwara H, Sunada Y (2004) Mechanism of taxane neurotoxicity. Breast Cancer 11:82–85

    Article  PubMed  Google Scholar 

  • Jain S, Vahdat LT (2011) Eribulin mesylate. Clin Cancer Res 17:6615–6622

    Article  PubMed  CAS  Google Scholar 

  • Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095

    Article  PubMed  CAS  Google Scholar 

  • Kuroi K, Shimozuma K (2004) Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 11:92–99

    Article  PubMed  Google Scholar 

  • Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39:368–373

    Article  PubMed  CAS  Google Scholar 

  • Mani S, Swami U (2010) Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc) 46:641–653

    Article  CAS  Google Scholar 

  • Mimura Y, Kato H, Eguchi K, Ogawa T (2000) Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 21:513–520

    PubMed  CAS  Google Scholar 

  • Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003–2011

    Article  PubMed  CAS  Google Scholar 

  • Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8:2086–2095

    Article  PubMed  CAS  Google Scholar 

  • Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G (2003) Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9:5756–5767

    PubMed  CAS  Google Scholar 

  • Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94:293–304

    Article  PubMed  CAS  Google Scholar 

  • Rowinsky EK (1993) Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 15:25–37

    PubMed  Google Scholar 

  • Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993a) Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107–115

    PubMed  Google Scholar 

  • Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993b) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15

    PubMed  CAS  Google Scholar 

  • Schmidt Y, Unger JW, Bartke I, Reiter R (1995) Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 132:16–23

    Article  PubMed  CAS  Google Scholar 

  • Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin—a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163–184

    Article  PubMed  Google Scholar 

  • Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954–2961

    Article  PubMed  CAS  Google Scholar 

  • Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD (2004) Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127:671–679

    Article  PubMed  Google Scholar 

  • Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J (1996) Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14:1993–1999

    PubMed  CAS  Google Scholar 

  • Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5:1232–1239

    PubMed  CAS  Google Scholar 

  • Wilson L, Jordan MA (2004) New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J Chemother 16(Suppl 4):83–85

    PubMed  CAS  Google Scholar 

  • Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, Slusher BS (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71:3952–3962

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NeuroTranslational Drug Discovery Program, Brain Science Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Krystyna M. Wozniak, Ying Wu & Barbara S. Slusher

  2. Departments of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Mohamed H. Farah & Barbara S. Slusher

  3. Departments of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Barbara S. Slusher

  4. Eisai Inc., Andover, MA, USA

    Bruce A. Littlefield & Kenichi Nomoto

Authors
  1. Krystyna M. Wozniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed H. Farah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce A. Littlefield
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara S. Slusher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara S. Slusher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wozniak, K.M., Wu, Y., Farah, M.H. et al. Neuropathy-Inducing Effects of Eribulin Mesylate Versus Paclitaxel in Mice with Preexisting Neuropathy. Neurotox Res 24, 338–344 (2013). https://doi.org/10.1007/s12640-013-9394-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12640-013-9394-3

Keywords

Search

Navigation